Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myeloproliferative Disorders 2Thrombocytosis 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Higher-risk Myelodysplastic Syndrome 1Hematologic Neoplasms 1Granulosa cell tumor of the ovary 1Anemia 1

Interventions

Specimen Handling 3Biopsy 3venetoclax 2trametinib 1siltuximab 1ruxolitinib 1regorafenib 1ponatinib 1pomalidomide 1pevonedistat 1pertuzumab 1pembrolizumab 1peginterferon alfa-2b 1palbociclib 1olaparib 1neratinib 1luspatercept 1lorlatinib 1lenvatinib 1idelalisib 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thrombocytosis × luspatercept × Clear all
NCT05005182 2024-09-19

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Mayo Clinic

Phase 2 Terminated
3 enrolled 12 charts
Myeloid

Myeloproliferative Disorders, Thrombocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡